[CLSTR]
< Back to situation

[REVISION HISTORY]

Aficamten development for hypertrophic cardiomyopathy

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-28 12:11 UTC → 2026-09-01 00:42 UTC · added removed

The cardiac myosin inhibitor aficamten (brand name Myqorzo) is expanding its clinical application and regulatory reach for hypertrophic cardiomyopathy (HCM). In England, the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence have authorized the drug for approximately 6,600 people with obstructive HCM. NICE guidance requires implementation within 90 days, with NHS England expected to make the treatment available within 30 days of final guidance. Clinical trials indicated the drug reduces symptoms like chest pain and breathlessness while improving exercise capacity. Concurrently, clinical data presented at the European Society of Cardiology Congress shows aficamten also significantly improves symptoms and exercise capacity in patients with the non-obstructive form of the condition (nHCM). In a study A Phase 3 trial published in the New England Journal of Medicine involving 517 patients, 53% of those receiving the drug showed meaningful patients met its primary endpoints, demonstrating improvements in peak oxygen uptake and clinical summary scores compared to 13% in a placebo group. placebo. Following these results, Cytokinetics plans to submit a supplemental U.S. marketing application for nHCM in the fourth quarter of 2026. Other therapeutic developments for HCM include Phase 2 data for EDG-7500, an experimental oral medication from Edgewise Therapeutics. This selective cardiac sarcomere modulator is designed to target both obstructive and nonobstructive forms of the disease by aiming to slow early contraction velocity and improve relaxation without compromising overall heart pumping function.

Versions

  1. 2026-09-01 00:42 UTC Aficamten development for hypertrophic cardiomyopathy
  2. 2026-08-28 12:11 UTC Aficamten development for hypertrophic cardiomyopathy

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.